Showing papers by "Jacques Buvat published in 2016"
••
TL;DR: PDE5 inhibitors remain a first-line treatment option because of their excellent efficacy and safety profile and intraurethral and topical alprostadil provide an alternative, less invasive treatment option.
147 citations
••
TL;DR: Level of evidence (LoEs) and grades of recommendations are provided based on a thorough analysis of the literature and committee consensus on the diagnosis and management of Testosterone deficiency.
130 citations